We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Argos Therapeutics announced that dosing has been initiated in a Phase I/II clinical trial to test the activity and safety of AGS-003, a personalized immunotherapy for advanced kidney cancer.
Vical has initiated an NIH-sponsored Phase I trial of a prime/boost vaccine approach designed to prevent or control disease in patients already infected with HIV.
Mission Pharmacal has submitted a supplemental new drug application with the FDA for a new indication for Tindamax (tinidazole) as treatment of bacterial vaginosis, the most common vaginal infection in the United States.
United Research Laboratories (URL) and Mutual Pharmaceutical have filed an abbreviated new drug application seeking approval to market Mutual's guaifenesin extended-release tablets, 600 mg and 1,200 mg.
Pharming Group announced that the European Medicines Agency (EMEA) has accepted its marketing authorization application for Rhucin (recombinant human C1 inhibitor) for the treatment of acute attacks of hereditary angioedema.